论文部分内容阅读
目的:通过对舒尼替尼进行预算影响分析,为药品报销目录的遴选决策制定提供科学依据。方法:构建预算影响分析模型,测算舒尼替尼在进入医保目录之后对医保支出的预期影响。结果:如果2015年舒尼替尼进入城镇医保目录,2015到2019年m RCC患者医保预算总费用较前一年的增幅分别为18.5%、23.1%、27.8%、32.4%和37.0%。结论:将舒尼替尼纳入城镇医保增加医保预算费用,增幅和各变量呈线性相关。
OBJECTIVE: To provide a scientific basis for the decision-making of drug reimbursement catalog through the analysis of the budget impact of sunitinib. Methods: Construct a budget impact analysis model to estimate the expected impact of sunitinib on Medicare expenditures after entering the Medicare directory. Results: If sunitinib entered the urban health insurance directory in 2015, the total medical insurance budget for patients with RCC from 2015 to 2019 increased by 18.5%, 23.1%, 27.8%, 32.4% and 37.0% respectively over the previous year. Conclusion: The cost of sunitinib into urban medical insurance to increase health insurance budget, the increase and the linear correlation between variables.